NeueHealth, Inc.
NEUE
$6.63
-$0.115-1.71%
| Weiss Ratings | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.75 | |||
| Price History | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.62% | |||
| 30-Day Total Return | -9.74% | |||
| 60-Day Total Return | 28.39% | |||
| 90-Day Total Return | 28.89% | |||
| Year to Date Total Return | -9.62% | |||
| 1-Year Total Return | -5.09% | |||
| 2-Year Total Return | -76.88% | |||
| 3-Year Total Return | -95.75% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -13.51% | |||
| 52-Week Low % Change | 74.80% | |||
| Price | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.66 | |||
| 52-Week Low Price | $3.79 | |||
| 52-Week Low Price (Date) | Dec 20, 2024 | |||
| 52-Week High Price (Date) | Feb 18, 2025 | |||
| Valuation | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 54.69M | |||
| Enterprise Value | 1.12B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -51.16 | |||
| Earnings Per Share Growth | -75.29% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.06 | |||
| Price/Book (Q) | -0.04 | |||
| Enterprise Value/Revenue (TTM) | 1.12 | |||
| Price | $6.63 | |||
| Enterprise Value/EBITDA (TTM) | -12.41 | |||
| Enterprise Value/EBIT | -9.98 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 8.28M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 612 238 1321 | |||
| Address | 9250 NW 36th St Doral, FL 33178 | |||
| Website | www.neuehealth.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -11.25% | |||
| Profit Margin | -36.28% | |||
| Management Effectiveness | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.10% | |||
| Return on Equity | -- | |||
| Income Statement | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 257.73M | |||
| Total Revenue (TTM) | 996.89M | |||
| Revenue Per Share | $120.37 | |||
| Gross Profit (TTM) | 174.78M | |||
| EBITDA (TTM) | -90.28M | |||
| EBIT (TTM) | -112.21M | |||
| Net Income (TTM) | -361.67M | |||
| Net Income Avl. to Common (TTM) | -361.67M | |||
| Total Revenue Growth (Q YOY) | -13.54% | |||
| Earnings Growth (Q YOY) | 94.57% | |||
| EPS Diluted (TTM) | -51.16 | |||
| EPS Diluted Growth (Q YOY) | 89.50% | |||
| Balance Sheet | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 118.68M | |||
| Cash Per Share (Q) | $14.33 | |||
| Total Current Assets (Q) | 589.43M | |||
| Total Preferred Equity (Q) | 920.42 | |||
| Total Equity (Q) | -312.52M | |||
| Current Ratio (Q) | 0.676 | |||
| Book Value Per Share (Q) | -$163.68 | |||
| Total Assets (Q) | 696.78M | |||
| Total Current Liabilities (Q) | 872.44M | |||
| Total Debt (Q) | 136.87M | |||
| Total Liabilities (Q) | 1.01B | |||
| Total Common Equity (Q) | -1.35B | |||
| Cash Flow | NEUE - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 163.42M | |||
| Cash from Financing (TTM) | -230.37M | |||
| Net Change in Cash (TTM) | -497.00M | |||
| Levered Free Cash Flow (TTM) | 724.36M | |||
| Cash from Operations (TTM) | -430.05M | |||
